These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 9323356

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A.
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [Abstract] [Full Text] [Related]

  • 4. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L, Casey DE, Hoffman WF, McCall AL.
    Arch Intern Med; 1993 Jun 28; 153(12):1469-75. PubMed ID: 8512437
    [Abstract] [Full Text] [Related]

  • 5. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study.
    Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A.
    Am J Psychiatry; 1987 Sep 28; 144(9):1148-53. PubMed ID: 2888321
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Movement disorders associated with neuroleptic treatment.
    Wirshing WC.
    J Clin Psychiatry; 2001 Sep 28; 62 Suppl 21():15-8. PubMed ID: 11584982
    [Abstract] [Full Text] [Related]

  • 8. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG.
    Can J Psychiatry; 1994 Nov 28; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998 Nov 28; 59 Suppl 12():23-7. PubMed ID: 9766616
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH, Byun HJ.
    Clin Neuropharmacol; 2003 Nov 28; 26(6):312-6. PubMed ID: 14646611
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The nosology of tardive syndromes.
    Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA.
    J Neurol Sci; 2018 Jun 15; 389():10-16. PubMed ID: 29433810
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P.
    Aust N Z J Psychiatry; 2004 Jun 15; 38(6):445-9. PubMed ID: 15209837
    [Abstract] [Full Text] [Related]

  • 18. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia.
    Brown KW, White T.
    Am J Psychiatry; 1992 Oct 15; 149(10):1385-9. PubMed ID: 1356314
    [Abstract] [Full Text] [Related]

  • 19. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN, Hoek HW, Matroos GE, van Os J.
    J Clin Psychiatry; 2006 Dec 15; 67(12):1920-7. PubMed ID: 17194270
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.